Key points are not available for this paper at this time.
You have accessJournal of UrologyProstate Cancer: Detection rates were similar for 3 and 4 ng/mL (Table 1). Among men with at least one PSA≥2.5 ng/mL in the study, 54% (95% CI 53%, 56%) had a level dropping below this threshold by the following year. Again, results were similar for higher thresholds. When excluding men with an initial PSA-level in the trial above the threshold, the proportions of PSAs decreasing below the threshold the following year were larger: around 40% at the PSA level and 65% at the patient level. CONCLUSIONS: In a large screening trial, we show that PSA levels measured at yearly intervals fluctuate which is why an isolated PSA elevation should be repeated. This supports guidelines that abnormal PSA results should be confirmed to minimize patient worry, unnecessary biopsy and risk of overdiagnosis of low-grade cancer. Source of Funding: NIH/NCI (P30-CA008748) (U01-CA266535) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e439 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Maria M. Pere More articles by this author Emily A. Vertosick More articles by this author Andrew J. Vickers More articles by this author Hans Lilja More articles by this author James A. Eastham More articles by this author Sigrid V. Carlsson More articles by this author Expand All Advertisement PDF downloadLoading ...
Pere et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: